Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEC, Liposomal Vincristine, Dexamethasone and Bortezomib in Relapsed/Refractory ALL and LL
NCT03136146Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2017
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies, Modified Peptides, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of clofarabine, etoposide, cyclophosphamide, vincristine sulfate liposome injection, dexamethasone in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), Burkitt leukemia, Burkitt lymphoma (BL), high-grade B-cell lymphoma with double-hit genetics (DHL), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2017; status: recruiting.
02
Drugs
clofarabineetoposidecyclophosphamidevincristine sulfate liposome injectiondexamethasone
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)Burkitt leukemiaBurkitt lymphoma (BL)high-grade B-cell lymphoma with double-hit genetics (DHL)
Beyond the preview
Go deeper on NCT03136146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03136146.